Targeting myocardial equilibrative nucleoside transporter ENT1 provides cardioprotection by enhancing myeloid Adora2b signaling
JCI Insight · 2023
DOI: 10.1172/jci.insight.166011 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2023. Verfasst von Wei Ruan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Critical Care and Pain Medicine, The University of Texas Health Science Center at Houston, McGovern Medical School, Hou…. Hauptthemen laut MEDLINE: Equilibrative Nucleoside Transporter 1, Myocardial Ischemia, Reperfusion Injury, Receptor, Adenosine A2B. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIGMS NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Previous studies implicate extracellular adenosine signaling in attenuating myocardial ischemia and reperfusion injury (IRI). This extracellular adenosine signaling is terminated by its uptake into cells by equilibrative nucleoside transporters (ENTs). Thus, we hypothesized that targeting ENTs would function to increase cardiac adenosine signaling and concomitant cardioprotection against IRI. Mice were exposed to myocardial ischemia and reperfusion injury. Myocardial injury was attenuated in mice treated with the nonspecific ENT inhibitor dipyridamole. A comparison of mice with global Ent1 or Ent2 deletion showed cardioprotection only in Ent1 –/– mice. Moreover, studies with tissue-specific Ent deletion revealed that mice with myocyte-specific Ent1 deletion ( Ent1 loxP/loxP Myosin Cre + mice) experienced smaller infarct sizes. Measurements of cardiac adenosine levels demonstrated that postischemic elevations of adenosine persisted during reperfusion after targeting ENTs. Finally, studies in mice with global or myeloid-specific deletion of the Adora2b adenosine receptor ( Adora2b loxP/loxP LysM Cre + mice) implied that Adora2b signaling on myeloid-inflammatory cells in cardioprotection provided by ENT inhibition. These studies reveal a previously unrecognized role for myocyte-specific ENT1 in cardioprotection by enhancing myeloid-dependent Adora2b signaling during reperfusion. Extension of these findings implicates adenosine transporter inhibitors in cardioprotection against ischemia and reperfusion injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Critical Care and Pain Medicine, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA.
- Department of Anesthesiology, Second Xiangya Hospital, Central South University, Changsha, China.
- Department of Cardiac Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
- Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
Förderung
- NIDDK NIH HHS
- NIGMS NIH HHS
- NHLBI NIH HHS
- NIAMS NIH HHS
- National Institutes of Health
- Department of Defense Grant
- 2022 International Anesthesia Research Society Mentored Research Award
- American Lung Association Catalyst Award
Zitieren
APA
Ruan, W., Li, J., Choi, S., Ma, X., Liang, Y., Nair, R., Yuan, X., Mills, T. W., & Eltzschig, H. K. (2023). Targeting myocardial equilibrative nucleoside transporter ENT1 provides cardioprotection by enhancing myeloid Adora2b signaling. JCI Insight. https://doi.org/10.1172/jci.insight.166011
Vancouver
Ruan W, Li J, Choi S, Ma X, Liang Y, Nair R, et al. Targeting myocardial equilibrative nucleoside transporter ENT1 provides cardioprotection by enhancing myeloid Adora2b signaling. JCI Insight. 2023. doi:10.1172/jci.insight.166011
BibTeX
@article{Ruan2023,
author = {Ruan, Wei and Li, Jiwen and Choi, Seungwon and Ma, Xinxin and Liang, Yafen and Nair, Ragini and Yuan, Xiaoyi and Mills, Tingting W and Eltzschig, Holger K},
title = {Targeting myocardial equilibrative nucleoside transporter ENT1 provides cardioprotection by enhancing myeloid Adora2b signaling},
journal = {JCI Insight},
year = {2023},
doi = {10.1172/jci.insight.166011}
}
EUVIMED